RIGL Latest Press Releases

-- October 29, 2026 --

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results PRNewswire 8:05 AM

-- October 19, 2026 --

Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 PRNewswire 8:05 AM

-- October 2, 2026 --

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PRNewswire 8:05 AM

-- September 2, 2026 --

Rigel to Participate in Upcoming September Investor Conferences PRNewswire 8:05 AM

-- August 13, 2026 --

Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer PRNewswire 8:05 AM

-- August 4, 2026 --

Rigel Reports Second Quarter 2026 Financial Results PRNewswire 4:01 PM

-- July 28, 2026 --

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results PRNewswire 8:05 AM

-- July 7, 2026 --

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PRNewswire 8:05 AM

-- July 1, 2026 --

Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer PRNewswire 8:05 AM

-- June 16, 2026 --

Rigel Announces Closing of Licensing Agreement for VEPPANU (vepdegestrant) PRNewswire 4:01 PM

Market Data Delayed 15 Minutes